Vifor Fresenius v. Aurobindo Pharma: 11-Patent VELPHORO® Dispute Dismissed in 146 Days
Vifor Fresenius Medical Care Renal Pharma filed suit against generic challenger Aurobindo Pharma in Delaware over 11 patents protecting VELPHORO®, its sucroferric oxyhydroxide phosphate binder. The case closed without prejudice after just 146 days, with the court retaining jurisdiction to enforce the parties’ resolution — a pattern consistent with a negotiated outcome.
Rapid ANDA dismissal in the renal phosphate-binder patent space
Vifor Fresenius Medical Care Renal Pharma Ltd. (Switzerland) and its French affiliate filed this infringement action on 10 August 2023 in the U.S. District Court for the District of Delaware before Judge Maryellen Noreika. The defendants — Aurobindo Pharma Ltd. and its U.S. subsidiary — are generic pharmaceutical manufacturers whose ANDA filing for sucroferric oxyhydroxide 500 mg chewable tablets triggered the suit. VELPHORO®, Vifor Fresenius’s branded product, is a phosphate binder indicated for hyperphosphatemia in dialysis patients, a high-value chronic-disease market.
The action concluded on 3 January 2024 — just 146 days after filing — via a joint stipulation under FRCP 41(a)(1)(A)(ii) and 41(c). All claims, counterclaims, and affirmative defenses were dismissed without prejudice, with each party bearing its own costs. Critically, the court retained jurisdiction to enforce and resolve disputes relating to the parties’ resolution, language that typically accompanies a confidential settlement or licensing agreement rather than a simple walk-away.
The 146-day duration is notably short for an 11-patent ANDA case in Delaware, suggesting the parties reached a resolution before significant merits litigation — likely before claim construction. The public record does not disclose financial terms, any patent licensing arrangement, or an agreed market-entry date for Aurobindo’s generic. The retention of court jurisdiction to enforce the resolution is the single most telling indicator that a substantive agreement underlies the dismissal, but its precise terms remain confidential.
Filing to voluntary dismissal in 146 days
146 days — well under the median ANDA patent case duration in Delaware
What the without-prejudice dismissal means for both parties
FRCP 41(a)(1)(A)(ii) — Stipulated dismissal by agreement
A Rule 41(a)(1)(A)(ii) dismissal requires the signed agreement of all parties. Unlike a unilateral plaintiff dismissal under Rule 41(a)(1)(A)(i), this mechanism signals mutual consent and typically reflects a negotiated resolution. The inclusion of Rule 41(c) extends the dismissal to counterclaims, ensuring Aurobindo’s invalidity and non-infringement defenses are also terminated without a merits ruling.
Bilateral — both sides agreedWithout prejudice: what the public record does — and does not — tell us
A dismissal without prejudice means Vifor Fresenius is not barred from refiling the same patent claims against Aurobindo. However, the public record does not specify whether the parties entered a formal settlement agreement, and if so, whether it contains a covenant not to sue or an agreed entry date. The absence of a with-prejudice dismissal does not confirm that no restrictions exist — it simply means the court order itself imposes none.
No merits ruling issuedCourt retains jurisdiction — a strong settlement signal
The stipulation expressly preserves Delaware District Court jurisdiction to enforce and resolve disputes arising from the parties’ resolution. Courts do not retain enforcement jurisdiction over bare walk-away dismissals. This clause is consistent with a confidential settlement agreement — such as a patent license or agreed generic launch date — that may require judicial enforcement if breached. It is among the clearest public indicators of a negotiated outcome in ANDA litigation.
Enforcement jurisdiction preservedEach party bears its own costs — no fee-shifting awarded
The stipulation expressly states no costs, disbursements, or attorneys’ fees are awarded to either party, except as specifically provided by the parties’ separate agreement. This standard cost allocation in agreed ANDA dismissals avoids any admission of wrongdoing or litigation weakness by either side. It also signals the case did not reach a stage — such as a finding of exceptional case status — that might trigger fee-shifting under 35 U.S.C. § 285.
No § 285 fee awardFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Vifor Fresenius Medical Care Renal Pharma, Ltd. | Company | Renal pharma IP holding entities — collectively holders of 11 VELPHORO® formulation patentsSearch in Eureka ↗ |
| Defendant | Aurobindo Pharma, Ltd. | Company | Aurobindo Pharma Ltd. and U.S. subsidiary — generics manufacturer seeking ANDA approval for sucroferric oxyhydroxide 500 mgSearch in Eureka ↗ |
| Plaintiff counsel | Brian E. Farnan | Attorney | Counsel for Vifor Fresenius Medical Care Renal Pharma, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Geoffrey A. Kirsner | Attorney | Counsel for Vifor Fresenius Medical Care Renal Pharma, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Matthew A. Traupman | Attorney | Counsel for Vifor Fresenius Medical Care Renal Pharma, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Michael J. Farnan | Attorney | Counsel for Vifor Fresenius Medical Care Renal Pharma, Ltd.Search in Eureka ↗ |
| Plaintiff counsel | Steven C. Cherny | Attorney | Counsel for Vifor Fresenius Medical Care Renal Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | George J. Barry , III | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | Michael P. Hogan | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | R. Touhey Myer | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Defendant counsel | Timothy H. Kratz | Attorney | Counsel for Aurobindo Pharma, Ltd.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Chief Judge | Delaware District Court — Chief JudgeSearch in Eureka ↗ |
Stipulation of dismissal — official text
The stipulation’s operative language — ‘dismissed without prejudice… without costs… except as specifically provided by agreement’ — is carefully constructed to preserve maximum flexibility for both parties while publicly disclosing nothing about the underlying terms. The carve-out phrase ‘except as specifically provided by agreement’ directly implies the existence of a separate private agreement governing costs or other financial terms. Combined with the express retention of court jurisdiction, the verdict language is structurally consistent with a confidential settlement incorporating licensing or market-entry terms rather than an unconditional withdrawal.
US10624855B2 and 10 further patents — VELPHORO® sucroferric oxyhydroxide formulation
The eleven patents asserted in this case cover sucroferric oxyhydroxide — a polynuclear iron(III)-oxyhydroxide compound complexed with sucrose and starches, approved under NDA 205109 as VELPHORO® for the control of serum phosphorus in chronic kidney disease patients on dialysis. The earliest application (US9561251B2, App. No. US12/743120) traces to an application filed approximately 2010, establishing foundational coverage, while the most recent (US11446252B2, App. No. US17/644612) reflects continued prosecution activity extending the portfolio’s effective life well into the 2030s. The cluster spans formulation, particle characteristics, and manufacturing methods.
The breadth of this 11-patent portfolio — spanning multiple application families filed across more than a decade — is a deliberate defensive architecture designed to make VELPHORO® difficult to genericise. VELPHORO® competes in the dialysis phosphate-binder market against sevelamer and lanthanum carbonate, and its sucroferric chemistry represents a distinct formulation class. For generic developers, the multi-family structure means that designing around one granted claim set does not clear the landscape; invalidity challenges would need to address each family independently, significantly raising the cost and risk of ANDA litigation.
Should your team run an FTO against the VELPHORO® patent cluster?
Any pharmaceutical manufacturer developing, formulating, or seeking ANDA approval for sucroferric oxyhydroxide 500 mg chewable tablets should treat this 11-patent portfolio as an active enforcement risk. The Vifor Fresenius v. Aurobindo outcome — a rapid, confidential resolution with court jurisdiction retained — demonstrates that the patent holders will assert this portfolio aggressively and negotiate from strength. Product teams working on iron-based phosphate binder formulations, even those with distinct particle profiles or excipient compositions, should confirm clearance before IND or ANDA filing.
PatSnap Eureka’s FTO Search Agent can map your compound and formulation claims against all 11 asserted patents simultaneously, identifying family-level overlap and flagging continuation risk from pending applications. Eureka’s claim monitoring feature can alert your team in real time if new continuation or divisional applications publish in these families — critical intelligence given the portfolio’s demonstrated pattern of ongoing prosecution activity across multiple application numbers.
Run a freedom-to-operate analysis on US10624855B2 to assess your product’s exposure
Run FTO in Eureka →Similar ANDA phosphate-binder patent cases in Delaware and beyond
PatSnap Eureka tracks related litigation across truck body equipment, vehicle accessories, and comparable infringement actions in the Georgia district system.
What this case signals for the renal pharma generic IP landscape
An 11-patent ANDA case resolved in under five months carries meaningful signals for brand and generic competitors in the phosphate-binder space.
Early ANDA resolutions in Delaware often indicate licensing, not capitulation
When a Delaware ANDA case with this many asserted patents closes before claim construction with court jurisdiction retained, the most probable explanation is a negotiated license or market-entry agreement. Generic challengers and brand holders in the renal space should treat this outcome as a commercial resolution, not a signal that the patent portfolio is weak or that early challenge is likely to succeed.
Vifor Fresenius’s 11-patent cluster creates a high barrier to generic VELPHORO® entry
Eleven asserted patents across multiple application families suggests layered claim coverage spanning formulation, manufacturing, and potentially method-of-treatment claims. Any generic entrant must design around or successfully challenge this entire cluster — not a single patent. The breadth of the portfolio, and Vifor Fresenius’s willingness to assert all 11 simultaneously, signals an aggressive enforcement posture consistent with protecting a high-value chronic-disease franchise.
Vifor v Aurobindo — key questions answered
The case was dismissed without prejudice by joint stipulation under FRCP 41(a)(1)(A)(ii). The public record does not disclose the specific reason, but the court’s retention of jurisdiction to enforce the parties’ resolution strongly suggests a private settlement — potentially including a patent license or agreed generic market-entry date — was reached between Vifor Fresenius and Aurobindo.
Eleven U.S. patents were asserted: US9561251B2, US10624855B2, US10682376B2, US10695367B2, US10925896B2, US10925897B2, US10933090B2, US11013761B1, US11013762B1, US11234938B2, and US11446252B2. All cover sucroferric oxyhydroxide formulations underlying the VELPHORO® 500mg chewable tablet product approved under NDA 205109.
When a court retains jurisdiction to enforce a resolution after dismissal, it typically means the parties have entered into a private agreement — such as a settlement, license, or consent order — whose terms may require judicial enforcement if breached. In ANDA litigation, this clause is a strong indicator of a negotiated outcome rather than an unconditional withdrawal by either party.
The dismissal without prejudice means the court order itself does not bar refiling. However, any private agreement between the parties — which is not publicly disclosed — may contain covenants not to sue or other restrictions. On the face of the public record alone, Vifor Fresenius retains the legal right to refile the same patent claims against Aurobindo.
The case lasted 146 days from filing (10 August 2023) to closure (3 January 2024). For an 11-patent ANDA infringement action in Delaware, this is notably short — the median lifespan of contested ANDA cases in Delaware typically runs to one to two years or longer. The speed of resolution is consistent with pre-claim-construction settlement, likely driven by the commercial complexity of a negotiated generic launch agreement.
PatSnap Eureka searches patents and litigation data to answer instantly.